Amgen and Zai Lab have agreed to run a global clinical trial combining two DLL3 targeted therapies for small cell lung cancer ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.

Amgen (AMGN) is drawing fresh attention after Phase 3 data for subcutaneous TEPEZZA in Thyroid Eye Disease and strong weight ...

Amgen announced 52-week results from a phase 2 trial with its weight-management candidate, MariTide. The results Amgen posted don't appear very competitive with Eli Lilly's weight management drug, ...

The findings could help Amgen defend Tepezza’s market-leading position against emerging rivals, though some analysts ...

Amgen's MariTide shows up to 20% weight loss in Phase II, leaving room for improvement beyond 52 weeks, as weight loss did not plateau. GI side effects are a concern, but Amgen plans to address them ...

Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is ...

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...

The drug, MariTide, also helped patients with obesity and Type 2 diabetes lose up to 17% of their weight after a year. The company said it did not observe a plateau in either group of patients, which ...

China approved Amgen’s tarlatamab for previously treated small cell lung cancer, expanding access to the bispecific immunotherapy. Amgen’s bispecific T-cell engager tarlatamab received regulatory ...

Amgen claims to have made weight loss history by producing the first proof of a reduction in body weight for a monthly obesity treatment in a phase 2 study—but it isn’t enough to enthuse investors.

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a new potential safety risk tied to the drug. Also Read: Jim Cramer Says Eli ...